Average Diluted Shares Outstanding: 243 million, 1% lower than a year ago. Cardinal Health Inc (NYSE:CAH) reported strong second quarter results, driven by robust demand in pharmaceutical and ...

Contrary to what we are led to believe, investors can only spend compound returns, not average returns. Nevertheless, the average returns are so often mentioned by those seeking to promote an ...

In this article, we are going to take a look at where Cardinal Health, Inc. (NYSE:CAH) stands against the other stocks. Mason Hawkins is a prominent figure in the world of value investing ...

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, announced positive topline results from an open-label, phase 2 congenital adrenal hyperplasia (CAH ... Crinetics’ second ...

Atumelnant, Crinetics’ second investigational compound, is the first once ... Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome.

Atumelnant, Crinetics' second investigational compound ... in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is currently ...

While Spruce Biosciences Inc.’s tildacerfont missed its phase II primary endpoint in classic congenital adrenal hyperplasia (CAH) last March, the U.S. FDA approved Crenessity (crinecerfont) from ...